Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer., PMID:20215530
Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer., PMID:20373269
GPNMB expression in uveal melanoma: a potential for targeted therapy., PMID:20375921
Gpnmb/osteoactivin, an attractive target in cancer immunotherapy., PMID:22017590
The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer., PMID:22229970
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer., PMID:23874106
Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE)., PMID:24496926
Novel data in metastatic breast cancer., PMID:24637556
New developments in metastatic breast cancer: integrating recent data into clinical practice., PMID:24892840
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program., PMID:24912408
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma., PMID:25267741
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer., PMID:25267761
Antibody-drug conjugate for advanced melanoma?, PMID:25602109
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer., PMID:25847941
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma., PMID:26305408
Emerging targeted therapies for melanoma., PMID:27148822
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB., PMID:27515299
Antibodies to watch in 2017., PMID:27960628
Novel Targeted Therapies for Metastatic Melanoma., PMID:28114255
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer., PMID:28546082
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent., PMID:29262642
Antibodies to watch in 2018., PMID:29300693
Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives., PMID:29439419
Antibody-drug conjugates in triple negative breast cancer., PMID:30175620
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma., PMID:30690710
Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives., PMID:31272342
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group., PMID:31586757
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma., PMID:32823698
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study., PMID:34016993
Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)., PMID:34590018
HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin., PMID:35110681
Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic., PMID:35267507
From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds., PMID:36160422
ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer., PMID:36900378
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB, PMID: 27515299
Novel data in metastatic breast cancer, PMID: 24637556
New developments in metastatic breast cancer: integrating recent data into clinical practice, PMID: 24892840
GPNMB expression in uveal melanoma: a potential for targeted therapy, PMID: 20375921
Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer, PMID: 20215530
Antibody-drug conjugate for advanced melanoma?, PMID: 25602109
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer, PMID: 23874106
Gpnmb/osteoactivin, an attractive target in cancer immunotherapy, PMID: 22017590
Antibodies to watch in 2018, PMID: 29300693
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent, PMID: 29262642
Antibodies to watch in 2017, PMID: 27960628
Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives, PMID: 29439419
Antibody-drug conjugates in triple negative breast cancer, PMID: 30175620
Emerging targeted therapies for melanoma, PMID: 27148822
Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives, PMID: 31272342
Novel Targeted Therapies for Metastatic Melanoma, PMID: 28114255
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer, PMID: 25267761
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study, PMID: 34016993
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma, PMID: 25267741
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer, PMID: 25847941
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group, PMID: 31586757
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma, PMID: 26305408
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program, PMID: 24912408
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma, PMID: 30690710
Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer, PMID: 20373269
Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE), PMID: 24496926
The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer, PMID: 22229970
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma, PMID: 32823698
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer, PMID: 28546082
For research use only. Not for human or drug use.
